Article

Navigating the commercialization of cell and gene therapies

This article was originally published on European Pharmaceutical Review (EPR) on May 19, 2025

Kevin Chinn, VP and Head of Cell and Gene Service Line at Cencora, talks about the hurdles to making cell and gene therapy a commercial success – and how to leap over them.

Read the article to explore the potential and major obstacles impacting cell and gene therapies in the pharmaceutical industry.

Pardot Form

Connect with our cell and gene experts

Our tailored solutions address the unique challenges of advanced therapies, from early discovery through to patient delivery, ensuring that innovative treatments reach those who need them most. Connect with our expert team today to learn how Cencora can support your product’s journey.
Abstract

Related resources

Article

Building an international pricing architecture for emerging biopharma

Webinar

Insight to impact: AI powered market access field optimization

Webinar

Accelerating access in FY27: Turning market shifts into action